+44 1300 500008Journal of Leukemia : Citations & Metrics Report
Articles published in Journal of Leukemia have been cited by esteemed scholars and scientists all around the world. Journal of Leukemia has got h-index 11, which means every article in Journal of Leukemia has got 11 average citations.
Following are the list of articles that have cited the articles published in Journal of Leukemia.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|
Year wise published articles |
62 | 23 | 11 | 8 | 22 | 23 |
Year wise citations received |
54 | 59 | 64 | 98 | 109 | 74 |
| Journal total citations count | 618 |
| Journal impact factor | 2.11 |
| Journal 5 years impact factor | 3.71 |
| Journal cite score | 3.91 |
| Journal h-index | 11 |
| Journal h-index since 2018 | 8 |
Important citations (462)
städler n, shang a, bosch f, briggs a, goede v, berthier a, renaudin c, leblond v. a systematic review and network meta-analysis to evaluate the comparative efficacy of interventions for unfit patients with chronic lymphocytic leukemia. advances in therapy. 2016 oct 1;33(10):1814-30. |
|
Edwards a, nalla p, premawardhana ld. a man with a short history of lower back pain. bmj. 2016 apr 7;353:i1722. |
|
Light chain myeloma: a brief report from india |
|
Epidemiology of multiple myeloma. inmultiple myeloma |
|
Investigating super-enhancer-associated chromatin interactions at the hoxa9-meis1 oncogene signalling axis in myeloid leukaemia |
|
Why imatinib is by far the best drug to treat chronic myeloid leukemia? |
|
Effects of aliskiren on hemodynamic parametersin daunorubicin -induced acute cardiomyopathy in rats |
|
huang xj, liu k, ritchie d, andersson b, lu j, hou j, de fuente burguera a, wang j, yeoh a, yan c, zhou d. hematology oncology practice in the asia-pacific aphcon survey results from the 6th international hematologic malignancies conference: bridging the gap 2015, beijing, china. oncotarget. 2017 jun 20;8(25):41620. |
|
ueno nt, fernandez jr, cristofanilli m, overmoyer b, rea d, berdichevski f, el-shinawi m, bellon j, le-petross ht, lucci a, babiera g. international consensus on the clinical management of inflammatory breast cancer from the morgan welch inflammatory breast cancer research program 10th anniversary conference. journal of cancer. 2018;9(8):1437. |
|
kamini j. why imatinib is by far the best drug to treat chronic myeloid leukemia. biochem mol biol lett. 2017;3(2):112. |
|
mahdiraji wg. electrical energy harvesting from cooker’s wasted heat with using conduction cooling. inmatec web of conferences 2018 (vol. 152, p. 02021). edp sciences. |
|
Kawaguchi-ihara n, zhao y, nakamura s, suzuki k, zhang yi, tohda s, murohashi i. chloroquine inhibits self-renewal of blast progenitors synergistically with phytochemicals or nonsteroidal anti-inflammatory drugs in hematological malignant cell lines. anticancer research. 2019 jan 1;39(1):87-98. |
|
Venetoclax: a first-in-class oral bcl-2 inhibitor for the management of lymphoid malignancies |
|
B-cell malignancies: the use of small molecule agents for treatment and management |
|
Therapeutic dendrimers |
|
Why imatinib is by far the best drug to treat chronic myeloid leukemia |
|
Shukla p. umbilical cord preservation-a review. biochem mol biol lett. 2017;3(1):109. |
|
Dhama n, babu a, sharma n. research & reviews: journal of medical and health sciences. |
|
Early mortality in multiple myeloma: the time-dependent impact of comorbidity: a population-based study in 621 real-life patients |
|
ríos-tamayo r, pérez mj, rodríguez ds, chang-chan yl. epidemiology of multiple myeloma. inmultiple myeloma 2018 nov 5. intechopen. |
|